Table 4.
Tumor type | Tumor cell line | Days of treat. | Dose mg/kg | Mice | Effects of Ivermectin | Ref. |
---|---|---|---|---|---|---|
Murine leukemia | MDAY-D2 | 10 | 3, | NOD/SCID mice | Reduces tumor volume up to 70% in all models | [44] |
5, | ||||||
6 | ||||||
i.p. | ||||||
Human leukemia | K562 | 3 oral | ||||
OCI-AML2 | ||||||
Human glioblastoma | U87 | 21 | 40 | SCID mice | Reduces tumor volume up to 50% | [47] |
T98G | i.p. | |||||
Breast cancer | MDA-MB-231-GFP | 10 | 2.4 | NOD/SCID mice | Reduces tumor volume up to 60% | [54] |
i.p. | ||||||
Human glioma | U87MG | 42 | 3, | Balb/c nude mice | Reduces tumor volume up to 50% at 3 mg/kg. | [64] |
10 | At 10 mg/kg tumors were not detectable | |||||
i.t. | ||||||
Human colon cancer | LDL1 | 21 | 10 | NMRI nude mice | Reduces tumor volume up to 85% (LDL1 cell line). No effect is observed in the tumor TCF-independent cell line (CC14) | [57] |
CC14 | i.p. | |||||
HT29 |
i.t.: intratumoral. i.p.: intraperitoneal.